Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence

다국어 초록 (Multilingual Abstract)

Background: Patient-centered management is becoming increasingly important in gout, but there are limited studies exploring patients' perspectives and preferences. We aimed to investigate patients' perspectives and preferences regarding gout and gout management, and their impacts on adherence to urate lowering therapy (ULT).
Methods: A paper-based survey was performed in patients with gout seen at the rheumatology outpatient clinics of 16 tertiary hospitals. The survey included questions regarding demographics, comorbidities, gout attacks, current treatment and adherence, and patients' perspectives and preferences regarding gout and gout management. Multivariate regression analysis was performed to determine the factors associated with ULT adherence.
Results: Of 809 surveyed patients with gout, 755 (94.5%) were using ULT. Among those using ULT, 89.1% had ≥ 80% adherence to ULT. Majority of the patients knew management strategies to some extent (94.8%), perceived gout as a life-long disease (91.2%), and were making efforts toward practicing at least one lifestyle modification (89.2%). Most patients (71.9%) obtained information about gout management during their clinic visits.
Approximately half of the patients (53.6%) preferred managing their disease with both ULT and lifestyle modification, 28.4% preferred ULT only, and 17.4% preferred lifestyle modification only. Adherence was better in patients with older age (odds ratio [OR], 1.03), those with better knowledge of gout management strategies (OR, 3.56), and those who had preference for ULT (OR, 2.07).
Conclusion: Patients' perspectives and management preferences had high impacts on adherence to ULT in gout. Consideration of patients' perspectives and preferences is important for achieving the desired clinical outcome in gout.

참고문헌 (Reference)

1 송정수, "한국인 맞춤형 통풍 치료 지침" 대한류마티스학회 20 (20): 280-285, 2013

2 Fraenkel L, "When patients write the guidelines: patient panel recommendations for the treatment of rheumatoid arthritis" 68 (68): 26-35, 2016

3 Jin Su Park, "Trends of Gout Prevalence in South Korea Based on Medical Utilization: A National Health Insurance Service Database (2002∼2015)" 대한류마티스학회 27 (27): 174-181, 2020

4 Kiltz U, "Treat-to-target(T2T)recommendations for gout" 76 (76): 632-638, 2017

5 Krahn M, "The next step in guideline development : incorporating patient preferences" 300 (300): 436-438, 2008

6 Hui M, "The British Society for Rheumatology guideline for the management of gout" 56 (56): e1-e20, 2017

7 Kuo CF, "Rising burden of gout in the UK but continuing suboptimal management : a nationwide population study" 74 (74): 661-667, 2015

8 Mattiuzzi C, "Recent updates on worldwide gout epidemiology" 39 (39): 1061-1063, 2020

9 Yin R, "Rate of adherence to urate-lowering therapy among patients with gout : a systematic review and meta-analysis" 8 (8): e017542-, 2018

10 주고운, "Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy" 대한의학회 29 (29): 657-661, 2014

11 Ji-Won Kim, "Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database" 대한내과학회 33 (33): 228-229, 2018

12 Rees F, "Patients with gout adhere to curative treatment if informed appropriately : proof-of-concept observational study" 72 (72): 826-830, 2013

13 Singh JA, "Patient perspectives on gout and gout treatments : a patient panel discussion that informed the 2020 American College of Rheumatology treatment guideline" 2 (2): 725-733, 2020

14 Spencer K, "Patient and provider barriers to effective management of gout in general practice : a qualitative study" 71 (71): 1490-1495, 2012

15 De Vera MA, "Medication adherence in gout: a systematic review" 66 (66): 1551-1559, 2014

16 Scheepers LE, "Medication adherence among patients with gout : a systematic review and meta-analysis" 47 (47): 689-702, 2018

17 Abhishek A, "Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study" 56 (56): 529-533, 2017

18 Dalbeth N, "Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability" 63 (63): 1605-1612, 2011

19 Doherty M, "Gout: why is this curable disease so seldom cured?" 71 (71): 1765-1770, 2012

20 Dalbeth N, "Gout" 5 (5): 69-, 2019

21 Doherty M, "Efficacy and costeffectiveness of nurse-led care involving education and engagement of patients and a treat-to-target uratelowering strategy versus usual care for gout : a randomised controlled trial" 392 (392): 1403-1412, 2018

22 Chen-Xu M, "Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends : the National Health and Nutrition Examination Survey, 2007–2016" 71 (71): 991-999, 2019

23 Briesacher BA, "Comparison of drug adherence rates among patients with seven different medical conditions" 28 (28): 437-443, 2008

24 Goodman SM, "Clinical practice guidelines:incorporating input from a patient panel" 69 (69): 1125-1130, 2017

25 Mikuls TR, "Adherence and outcomes with urate-lowering therapy : a site-randomized trial" 132 (132): 354-361, 2019

26 Singh JA, "A cross-sectional internet-based patient survey of the management strategies for gout" 16 (16): 90-, 2016

27 FitzGerald JD, "2020American College of Rheumatology guideline for the management of gout" 72 (72): 744-760, 2020

28 Richette P, "2016 updated EULAR evidence-based recommendations for the management of gout" 76 (76): 29-42, 2017

29 Morris C, ""It's complicated"-talking about gout medicines in primary care consultations : a qualitative study" 17 (17): 114-, 2016